Pioglitazone, a PPARγ agonist, was shown to restore cholesterol clearance of Csf2−/− and Csf2rb−/− AMs in vitro and in vivo and thereby decrease PAP disease severity [24]. Here, CSF2 is linked to pulmonary alveolar proteinosis.